Therapeutic Asset Ratings
178 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Vidutolimod
Stage IV Prostate Cancer AJCC v8
Emory University
P2
CC
(45)
TIPIRACIL
Pancreatic Adenocarcinoma
Emory University
P1/2
CC
(45)
Trifluridine
Pancreatic Adenocarcinoma
Emory University
P1/2
CC
(45)
Lutetium Lu 177 Psma-10.1
Prostate Carcinoma
Emory University
P1
CC
(43)
Mrx-2843
Non-Small Cell Lung Carcinoma
Emory University
P1
CC
(43)
Pepinemab
Cutaneous Melanoma
Emory University
P1
CC
(43)
TIPIRACIL
Gastric Adenocarcinoma
Emory University
P1/2
CC
(43)
Trifluridine
Gastric Adenocarcinoma
Emory University
P1/2
CC
(43)
Mrx-2843
Lung Cancer
Emory University
P1
CC
(41)
Verteporfin
Glioblastoma
Emory University
P1/2
CC
(41)
Lutetium Lu 177 Psma-10.1
Prostate Adenocarcinoma
Emory University
P1
C
(39)
SIMVASTATIN
Her2-Receptor Negative Breast Cancer
Emory University
Early P1
C
(39)
SIMVASTATIN
Hormone Receptor-Positive Breast Cancer
Emory University
Early P1
C
(39)
Triiodothyronine
Gliosarcoma
Emory University
Early P1
C
(39)
Methimazole
Gliosarcoma
Emory University
Early P1
C
(38)
Prometrium
Gliosarcoma
Emory University
Early P1
C
(38)
Prometrium
Glioblastoma
Emory University
Early P1
C
(38)
Vudalimab
Prostate Carcinoma
Emory University
P1
C
(37)
Vudalimab
Prostate Adenocarcinoma
Emory University
P1
C
(37)
Vudalimab
Prostate Cancer
Emory University
P1
C
(37)
Leucine
PKU
Emory University
N/A
D
(30)
Octanate
Hemophilia A
Emory University
D
(30)
Palynziq
Phenylketonuria
Emory University
D
(30)
Quadrivalent Inactivated Influenza Vaccine
Diffuse Large B-Cell Lymphoma
Emory University
D
(30)
Quadrivalent Inactivated Influenza Vaccine
Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma
Emory University
D
(30)
Showing 151 to 175 of 178 assets
Previous
Page 7 of 8
Next